CN116621975A - Humanized monoclonal antibody aiming at Nipah virus G protein and application thereof - Google Patents
Humanized monoclonal antibody aiming at Nipah virus G protein and application thereof Download PDFInfo
- Publication number
- CN116621975A CN116621975A CN202310743583.6A CN202310743583A CN116621975A CN 116621975 A CN116621975 A CN 116621975A CN 202310743583 A CN202310743583 A CN 202310743583A CN 116621975 A CN116621975 A CN 116621975A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- nipah virus
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000526636 Nipah henipavirus Species 0.000 title claims abstract description 51
- 108091006027 G proteins Proteins 0.000 title claims description 19
- 102000030782 GTP binding Human genes 0.000 title claims description 19
- 108091000058 GTP-Binding Proteins 0.000 title claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 229940126585 therapeutic drug Drugs 0.000 claims description 5
- 229940127121 immunoconjugate Drugs 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 229940043274 prophylactic drug Drugs 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 abstract description 10
- 241000699800 Cricetinae Species 0.000 abstract description 7
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000006386 neutralization reaction Methods 0.000 abstract description 4
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 241000700605 Viruses Species 0.000 description 18
- 241001112090 Pseudovirus Species 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 101710091045 Envelope protein Proteins 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 102100021696 Syncytin-1 Human genes 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- 241000288673 Chiroptera Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000000464 Henipavirus Infections Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010064034 Nipah virus infection Diseases 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000010069 protein adhesion Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Abstract
The antibody provided by the application can specifically and high-affinity bind with the nipah virus envelope protein, has effective neutralization activity on the nipah virus taking VSV as a framework, can effectively neutralize the nipah virus on a cellular level, and can completely protect hamsters infected with the nipah virus. Which are directed against epitopes different from the neutralizing epitopes reported. Therefore, the series of antibodies are hopefully used as novel specific antibody medicines for preventing and treating the Nipah virus, and provide more choices for preventing and controlling the Nipah virus.
Description
Technical Field
The application relates to the technical field of biomedical engineering, in particular to a humanized monoclonal antibody aiming at Nipag virus G protein and application thereof.
Background
Nipah virus (NiV) is a negative strand RNA virus belonging to Paramyxoviridae, henry. Nipah virus has a wide host range and can infect multiple species of mammals, and in the natural ecosystem, the virus can infect humans through natural host bats in two ways, firstly, can be transmitted to humans through intermediate host poultry, and the other way is that the direct contact of humans and bats causes infection. Once infected, can cause acute, highly fatal infectious diseases with central nervous system, respiratory system as the primary pathology. Since the first infection of nipah virus in malaysia in 1988, the number of nipah virus infections published by the world health organization has reached 336, the mortality has reached 260, and the mortality has reached 77%. Due to the high virulence, broad host range of nipah viruses, and the current lack of specific effective prophylactic and therapeutic drugs, these are classified as Biosafety Level 4 pathogens.
The genome of nipah virus is an approximately 18kb single-stranded negative-strand RNA molecule encoding 6 proteins. Two of the protein adhesion proteins G and fusion protein F are major surface glycoproteins of pathogens. The G protein is a type II transmembrane glycoprotein, which is in tetrameric form on the viral surface. G-H loop of cell membrane surface protein erphrinB2/3 is inserted into the hydrophobic groove of G protein, and through hydrophobic interaction, the virus is attached to the cell surface to mediate the combination of the virus and the cell; the F protein promotes fusion of the virus with the cell membrane and fusion of the membrane of the infected cell with the membrane of the adjacent cell at the initial stage of the infection cycle to form a characteristic syncytium. The adhesion protein G binds to the cell surface receptor and acts with F to induce a conformational change in the F protein, which causes membrane fusion to occur, thereby releasing the viral ribonucleoprotein complex into the cytoplasm of the host cell.
Phage display technology is to fuse the displayed gene with phage self-protein gene (gIII or gVIII) and display it on the surface of phage. Can build a large capacity (10 10 ～10 11 ) The display library of the system is screened, and the system is more and more valued by the unique advantages of high speed, short period and the like. The recombination of antibody molecule gene level can obtain various specific mouse-source, humanized and fully human antibody molecules and fragments. The technical field of phage display technology and antibody genetic engineering combined generation is currently in the fieldThe rapid development stage, the technology enables the development and research of the fully human monoclonal antibody to step into a substantial application stage and a development stage from a basic research stage, and brings new hopes for preventing and treating infectious diseases.
Disclosure of Invention
Aiming at the problems in the prior art, the application provides a humanized monoclonal antibody aiming at Nipagin G protein and application thereof.
The application uses human sourcesThe Fab phage display library uses Nipah virus G protein as antigen, carries out panning (panning) of anti-Nipah virus humanized antibody, uses a prokaryotic expression system to express and purify to obtain candidate clone protein, and carries out identification and evaluation on biological specificity, pseudovirus neutralization activity on cell level and protection effect on infected animals to obtain four fully human Nipah virus antibodies NiV41, 41-4, 41-6 and 41-9.
Specifically, the heavy chain variable region of the NiV41 antibody contains the amino acid sequence shown in Seq ID No.4 with amino acid sequences shown in SEQ ID No. 1-3 at positions 26-33, 51-58 and 97-120, respectively, while 41-4, 41-6 and 41-9 have identical heavy chains and light chains are different, the light chain variable region having three CDRs, LCDR1, LCDR2 and LCDR 3.
The light chain of NiV41 comprises the amino acid sequence shown as SEQ ID No.8, LCDR1 comprises the amino acid sequence shown as SEQ ID No.5, LCDR2 comprises the amino acid sequence shown as SEQ ID No.6, and LCDR3 comprises the amino acid sequence shown as SEQ ID No. 7.
41-4 comprising the amino acid sequence shown in SEQ ID No.12, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID No.9, LCDR2 comprises the amino acid sequence shown in SEQ ID No.10, and LCDR3 comprises the amino acid sequence shown in SEQ ID No. 11.
41-6, wherein LCDR1 comprises the amino acid sequence shown as SEQ ID No.16, LCDR2 comprises the amino acid sequence shown as SEQ ID No.14, and LCDR3 comprises the amino acid sequence shown as SEQ ID No. 15.
41-9 comprises the amino acid sequence shown as SEQ ID No.20, LCDR1 comprises the amino acid sequence shown as SEQ ID No.17, LCDR2 comprises the amino acid sequence shown as SEQ ID No.18, and LCDR3 comprises the amino acid sequence shown as SEQ ID No. 19.
The application also discloses an antigen binding fragment, which comprises the antibody heavy chain variable region aiming at the Nipah virus G protein, and a bispecific antibody, which comprises the antibody heavy chain variable region aiming at the Nipah virus G protein, or the Nipah virus antibody.
The application also discloses application of the antibody heavy chain variable region aiming at the Nipah virus G protein, the Nipah virus antibody and the antigen binding fragment in preparing preventive and therapeutic drugs aiming at the Nipah virus, detection probes, fusion polypeptides, fusion proteins, immunoconjugates and genetically engineered host cells.
The fully human monoclonal antibody against the Nipah virus provided by the application is obtained by the following method: first, constructing human sourceAnd (3) the Fab phage display library, and then 4 rounds of screening by taking the extracellular domain of the nipah virus envelope protein expressed by a mammalian cell expression system as an antigen, so as to obtain an enriched and high-affinity clone NiV41. The clone is expressed and purified, and is identified and evaluated, and the biological atopy, the pseudovirus neutralization activity on the cellular level and the infected animal protection effect of the clone are identified and evaluated, so that the antibody can effectively neutralize the Nipagin. Meanwhile, an affinity maturation library is constructed by a light chain substitution mode, and three clones 41-4, 41-6 and 41-9 which are enriched and have high affinity are obtained by taking the extracellular domain of the nipah virus envelope protein as an antigen and screening. The structure prediction of antigen-antibody complex based on Alpha Fold2 shows (see figure 6), that the series of antibodies mainly act through heavy chain, the heavy chain CDR3 acts on the central recess of antigen protein to compete for binding to envelope protein G protein and receptor binding site, thereby inhibiting virusInfection.
The beneficial effects of the application are as follows: the provided antibody can specifically bind with high affinity to the nipah virus envelope protein, has effective neutralization activity on the nipah pseudovirus taking VSV as a framework, can effectively neutralize the nipah virus at a cellular level, and can completely protect hamsters infected with the nipah virus. Which are directed against epitopes different from the neutralizing epitopes reported. Therefore, the series of antibodies are hopefully used as novel specific antibody medicines for preventing and treating the Nipah virus, and provide more choices for preventing and controlling the Nipah virus.
Drawings
Fig. 1: and (5) expressing and purifying the nipah virus envelope protein G protein. The target protein is detected by polyacrylamide gel electrophoresis (SDS-PAGE), lane M is a molecular weight standard, and lane G-Fc is the target protein.
Fig. 2: niV41 IgG, 41-4IgG, 41-6IgG and 41-9IgG antibodies were purified and then detected by SDS-PAGE. Lanes NiV41, 41-4, 41-6, 41-9 are the proteins of interest.
Fig. 3: binding of NiV41 IgG, 41-4IgG, 41-6IgG to 41-9IgG and Nipah virus envelope protein as determined by ELISA. The binding concentration EC50 of NiV41 IgG and antigen protein was 1.8. Mu.g/ml, the binding concentration EC50 of 41-4IgG and antigen protein was 0.21. Mu.g/ml, the binding concentration EC50 of 41-6IgG and antigen protein was 0.1. Mu.g/ml, and the binding concentration EC50 of 41-9IgG and antigen protein was 0.06. Mu.g/ml.
Fig. 4: niV41 IgG, 41-4IgG, 41-6IgG and 41-9IgG and Nipag pseudovirus experiments. The neutralizing activity IC50 of NiV41 IgG and Nipah pseudovirus is 0.01 mug/ml, the neutralizing activity IC50 of 41-4IgG and Nipah pseudovirus is 0.005 mug/ml, the neutralizing activity IC50 of 41-6IgG and Nipah pseudovirus is 0.002 mug/ml, and the neutralizing activity IC50 of 41-9IgG and Nipah pseudovirus is 0.002 mug/ml.
Fig. 5: niV41 IgG, 41-4IgG, 41-6IgG and 41-9IgG and Nipag live virus experiments. The neutralizing activity IC50 of NiV41 IgG and Nipah live virus is 0.33 mug/ml, the neutralizing activity IC50 of 41-4IgG and Nipah live virus is 0.136 mug/ml, the neutralizing activity IC50 of 41-6IgG and Nipah live virus is 0.088 mug/ml, and the neutralizing activity IC50 of 41-9IgG and Nipah live virus is 0.059 mug/ml.
Fig. 6:41-6 interact with the antigenic protein NiV-G. Antigen-antibody complex structure prediction was performed by Alpha Fold2 prediction software, and antibody 41-6 was involved in the interaction with antigen primarily through the CDR3 region of the heavy chain.
Fig. 7: niV41 IgG, 41-6IgG animal protection experiments. NiV41 IgG provides complete therapeutic protection against infected animals, 41-6IgG provides complete prophylactic protection against infected animals, and the negative control is PBS.
Detailed Description
The present application will be described in detail with reference to the following examples and the accompanying drawings, wherein the following examples are given by way of illustration of the present application and specific embodiments and specific procedures thereof, but the scope of the present application is not limited to the following examples.
Example 1: expression and purification of nipah virus envelope proteins
According to the gene sequence of Nipag virus (GenBank NC-002728.1), the extracellular domain (amino acids 188-602) of the envelope protein is spliced with the Fc gene sequence of IgG1 type, and the spliced gene is connected with the vector pSecTag2A for transformation to construct the vector pSecTag2A-G-Fc. 293F cells (control cell density 5 to 10) were grown 1 day prior to transfection 5 40 mL) was inoculated into 125mL suspension cell culture flasks. Mu.g of plasmid (pSecTag 2A-G-Fc) was diluted and gently homogenized in 4mL of DPBS buffer, and 120. Mu.L of PEI (polyethylenimine) was further diluted and gently homogenized in the culture medium. After incubation for 20 minutes at room temperature, they were added dropwise to the cells. The cells were placed in a suspension incubator at 125 rpm and incubated at 37 ℃.
After 144 hours, culture supernatants were collected and expression of antigen proteins was detected by Western blotting (Western Blot) using anti-Fc as primary antibody.
After the detection of G-Fc expression, the cell culture and transfection scale was enlarged and the G-Fc protein was expressed in large amounts. The culture supernatant was collected, the target protein was purified by protein A packing, and then the buffer was replaced by ultrafiltration with an ultrafiltration centrifuge tube having a molecular weight cut-off of 10kDa, and the purity was confirmed by SDS-PAGE, and the results are shown in FIG. 1.
Example 2: construction and screening of phage display libraries
Screening was performed with antigens expressed by mammalian cells using the constructed phage library. After the purified antigen is incubated in a 96-well plate at 4 ℃ overnight, panning is performed in a phage library, specific phage are captured by the antigen, PBS+0.05% Tween-20 is used for cleaning, and enrichment clone is obtained after 4 rounds of screening and named NiV41.
The gene encoding the antibody light chain fragment is obtained and amplified in large quantity by PCR on donor RNA which is derived from healthy and non-immune, a new affinity maturation library of light chain shuffling is obtained by enzyme digestion connection mode on the basis of the antibody gene of parent clone NiV41, and G-Fc protein is used for screening to obtain enrichment clones named 41-4, 41-6 and 41-9 respectively.
Example 3: expression purification of NiV41 IgG, 41-4IgG, 41-6IgG and 41-9IgG
The heavy and light chains of NiV41 Fab, 41-4Fab, 41-6Fab and 41-9Fab were constructed into the IgG1 expression vector pivotr 2-neo-mcs (commercially available), expressed by PEI transfection of 293F cells, the expression supernatant was purified with protein A filler, and then the buffer was ultrafiltration-replaced with an ultrafiltration centrifuge tube of 30kDa cut-off, and the purity was confirmed by SDS-PAGE, as shown in FIG. 2.
Example 4: ELISA assay for binding of NiV41 IgG, 41-4IgG, 41-6IgG to 41-9IgG and envelope protein
Envelope proteins (4. Mu.g/mL) were coated on ELISA plates and incubated overnight at 4℃and blocked with PBS+3% mill for 1h at 37 ℃. Serial dilutions of antibodies were added, incubated for 2 hours at 37 ℃ and then washed four times with PBST (pbs+0.05% tween 20), and horseradish peroxidase (HRP) -labeled murine anti-human Fc monoclonal antibody was added, incubated for 1 hour at 37 ℃ and then washed four times with PBST and then ABTS was added for detection. Binding affinities of the individual antibodies were calculated by the data analysis software Prism fit. The results are shown in FIG. 3.
Example 5: niV41 IgG, 41-4IgG, 41-6IgG and 41-9IgG antibodies neutralized Nipajamas in Vero cells.
mu.L of Vero cells (1X 10) 5 Each ml) was inoculated into a 96-well plate and cultured for 14 to 16 hours. Pressing the buttonAn equal volume of Nipah virus pseudovirus was mixed with the antibody dilution at an initial final antibody concentration of 100. Mu.g/ml, diluted in a three-fold gradient, and incubated for 1 hour at 37 ℃. The cell culture medium in the 96-well plate was discarded, and the cells were infected with a virus and antibody mixture, and were subjected to stationary culture at 37℃for 24 hours. The following day the cells were observed for fluorescence under a fluorescence microscope. By high content scanning, the fluorescence intensity of each well plate was analyzed, the weaker the fluorescence, indicating that fewer cells were infected with pseudoviruses, i.e., more pseudoviruses were neutralized by the antibody. Half maximal inhibitory activity (IC 50) of each antibody was calculated by data analysis software Prism. The results are shown in FIG. 4.
Example 6: antibodies NiV41 IgG, 41-4IgG, 41-6IgG and 41-9IgG neutralize Nipah live virus.
0.5mL of Vero cells (1X 10) 5 Each ml) was inoculated with a 24-well plate and cultured for 14 to 16 hours. According to the constant concentration of 100ug/ml of antibody, three-fold gradient dilution is carried out, and the equal volume of Nipag live virus is mixed with the antibody diluent and incubated for 1 hour at 37 ℃. The cell culture medium in the 24-well plate was discarded, and the cells were infected with a virus and antibody mixture, and were subjected to stationary culture at 37℃for 1 hour. Removing virus-antibody mixed solution in cell plate, adding culture medium containing carboxymethyl cellulose, standing at 37 deg.C for 4-5 days. After the cell well plate was subjected to inactivation treatment, the formation and the number of plaques were observed and counted by crystal violet staining. Fewer plaques indicates fewer cells infected with the virus, i.e., more pseudoviruses neutralized by the antibody. Half maximal inhibitory activity (IC 50) of each antibody was calculated by data analysis software Prism. The results are shown in FIG. 5.
Example 7: interface prediction of interaction of antibody 41-6 with antigen
The sequences of the antibody Fab fragments and the antigen sequences are written into a text, the structure of an antigen antibody complex is predicted in a multimeric form through an Alpha Fold2 database, the structure generated by prediction is analyzed, and the structure with the highest score ranking is selected. Complex interaction interfaces were analyzed in the software PDBePISA. The results are shown in FIG. 6.
Example 8: protection of hamsters infected with Nipag virus by antibodies NiV41 IgG, 41-6IgG
Four-five week old female hamsters were inoculated with a dose of the Bengalenical strain (NiV by intraperitoneal injection B ) After 6 hours of infection, 300 μg of IgG antibody NiV41 was injected into each experimental animal by intraperitoneal injection, PBS was selected as a negative control, hamster body condition was observed daily and survival was recorded;
four-five week old female hamsters were given 1mg of IgG antibody 41-6 per experimental animal by intraperitoneal injection, PBS as a negative control. One day after prophylactic administration, a dose of malaysia-series nipah virus (NiV M ). Hamster physical status was observed daily and survival was recorded.
The above experiments were performed in a biosafety quaternary laboratory. The experimental results are shown in FIG. 7.
The present application may be better understood and appreciated by those skilled in the art by reference to the examples. However, the protection of the application and the scope of the claims are not limited to the cases provided. All other embodiments, which can be made by one of ordinary skill in the art without undue burden on the person of ordinary skill in the art based on embodiments of the present application, are within the scope of the present application.
Claims (10)
1. An antibody heavy chain variable region directed against nipah virus G protein, characterized by: the heavy chain variable region has three complementarity determining regions CDRs of HCDR1, HCDR2 and HCDR3, the HCDR1 comprising the amino acid sequence shown in SEQ ID No. 1; the HCDR2 comprises an amino acid sequence shown as SEQ ID No. 2; the HCDR3 comprises an amino acid sequence as shown in SEQ ID No. 3.
2. The antibody heavy chain variable region against nipah virus G protein as set forth in claim 1, wherein: the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID No. 4.
3. A nipah virus antibody comprising the antibody heavy chain variable region of claim 1 or 2 directed against a nipah virus G protein.
4. The nipah virus antibody of claim 3 having a light chain, wherein: the variable region of the light chain has three complementarity determining regions CDRs, LCDR1, LCDR2 and LCDR3, selected from the group consisting of:
the LCDR1 comprises an amino acid sequence shown as SEQ ID No. 5; the LCDR2 comprises an amino acid sequence shown as SEQ ID No. 6; the LCDR3 comprises an amino acid sequence shown as SEQ ID No. 7; or (b)
The LCDR1 comprises an amino acid sequence shown as SEQ ID No. 9; the LCDR2 comprises an amino acid sequence shown as SEQ ID No. 10; the LCDR3 comprises an amino acid sequence shown as SEQ ID No. 11; or (b)
The LCDR1 comprises an amino acid sequence shown as SEQ ID No. 13; the LCDR2 comprises an amino acid sequence shown as SEQ ID No. 14; the LCDR3 comprises an amino acid sequence shown as SEQ ID No. 15; or (b)
The LCDR1 comprises an amino acid sequence shown as SEQ ID No. 17; the LCDR2 comprises an amino acid sequence shown as SEQ ID No. 18; the LCDR3 comprises an amino acid sequence as shown in SEQ ID No. 19.
5. The nipah virus antibody of claim 4, wherein: the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID No.8, SEQ ID No.12, SEQ ID No.16, or SEQ ID No. 20.
6. An antigen binding fragment comprising the antibody heavy chain variable region of claim 1 or 2 against nipah virus G protein.
7. A bispecific antibody comprising the antibody heavy chain variable region of claim 1 or 2 against nipah virus G protein, or the nipah virus antibody of any one of claims 3-5.
8. Use of the heavy chain variable region of an antibody against nipah virus G protein according to claim 1 or 2 for the preparation of a prophylactic and therapeutic drug against nipah virus, a detection probe, a fusion polypeptide, a fusion protein, an immunoconjugate, a genetically engineered host cell.
9. Use of the nipah virus antibodies of claim 3 or 4 or 5 for the preparation of prophylactic and therapeutic drugs, detection probes, fusion polypeptides, fusion proteins, immunoconjugates, genetically engineered host cells against nipah virus.
10. Use of the antigen binding fragment of claim 6 for the preparation of a prophylactic and therapeutic drug against nipah virus, a detection probe, a fusion polypeptide, a fusion protein, an immunoconjugate, a genetically engineered host cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310743583.6A CN116621975A (en) | 2023-06-21 | 2023-06-21 | Humanized monoclonal antibody aiming at Nipah virus G protein and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310743583.6A CN116621975A (en) | 2023-06-21 | 2023-06-21 | Humanized monoclonal antibody aiming at Nipah virus G protein and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116621975A true CN116621975A (en) | 2023-08-22 |
Family
ID=87592172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310743583.6A Pending CN116621975A (en) | 2023-06-21 | 2023-06-21 | Humanized monoclonal antibody aiming at Nipah virus G protein and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116621975A (en) |
-
2023
- 2023-06-21 CN CN202310743583.6A patent/CN116621975A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kreer et al. | Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients | |
| CN107847591B (en) | Multivalent human immunodeficiency virus antigen binding molecules and uses thereof | |
| CN116063464A (en) | Antibodies or antigen binding fragments thereof to coronaviruses | |
| WO2020038147A1 (en) | Anti-bcma single domain antibodies and application thereof | |
| CN113354729B (en) | Monoclonal antibody for resisting novel coronavirus and application thereof | |
| CN110317267B (en) | Bispecific antibodies against rabies virus and uses thereof | |
| CN116023478A (en) | Neutralizing antibodies or antigen binding fragments thereof for coronaviruses | |
| US20170158753A1 (en) | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species | |
| US20090004198A1 (en) | Human monoclonal antibody binding to human cytomegalovirus and its antigen binding portion | |
| CN106459186B (en) | Broadly neutralizing monoclonal antibodies against the ENV region of HIV-1V 2 | |
| CN113416245A (en) | Neutralizing antibody capable of combining SARS-CoV-2 virus RBD protein and application thereof | |
| CN113354730B (en) | Monoclonal antibody for resisting novel coronavirus and application thereof | |
| KR102504884B1 (en) | Nanoantibodies capable of binding to SFTSV and applications thereof | |
| WO2020186687A1 (en) | Human antibody specifically binding four serotypes of dengue viruses | |
| US20230399384A1 (en) | Antibodies to coronavirus spike protein and methods of use thereof | |
| Yang et al. | Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V (D) J sequencing | |
| Sullivan et al. | Harnessing the immune system's arsenal: producing human monoclonal antibodies for therapeutics and investigating immune responses | |
| CN114805579B (en) | Anti-human ACE2 protein monoclonal antibody, nucleic acid molecule and application | |
| Pavan et al. | Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants | |
| CN113698487B (en) | Anti-human ACE2 monoclonal antibody and application thereof | |
| CN116621975A (en) | Humanized monoclonal antibody aiming at Nipah virus G protein and application thereof | |
| CN116574178A (en) | Neutralizing humanized monoclonal antibody of Nipah virus and application thereof | |
| Han et al. | Purification and characterization of monoclonal IgG antibodies recognizing Ebola virus glycoprotein | |
| CN114790240B (en) | SARS-CoV-2 neutralizing monoclonal antibody and application | |
| US20230159652A1 (en) | Transferrin receptor 1 targeting for carcinogenesis prevention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |